Differential use of CCR5 vs. CXCR4 by HIV-1. Pathogenic, Translational and Clinical Open Questions
2011
Differential use of CCR5 versus CXCR4 by HIV-1
publication
Author Information
Author(s): Guido Poli, Luigi Buonaguro
Primary Institution: San Raffaele Scientific Institute
Conclusion
The study highlights the importance of CCR5 and CXCR4 in HIV-1 infection and their implications for treatment and prevention strategies.
Supporting Evidence
- The discovery of CCR5 and CXCR4 as HIV-1 co-receptors was a major milestone in AIDS research.
- Maraviroc, an anti-HIV drug, blocks CCR5 and has been licensed for treatment.
- CCR5 is the key co-receptor driving the AIDS pandemic, while CXCR4 is associated with advanced disease.
Takeaway
HIV uses two main doors to enter our immune cells, and understanding how these doors work can help us find better treatments.
Limitations
The study discusses limitations of non-human primate models that only use CXCR4.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website